Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of QL1706 in previously treated unresectable or metastatic urothelial carcinoma
ChiCTR2600117416Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in transitional cell carcinoma (TCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2600117416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117416.